Investors of Pacira BioSciences Inc. Urged to Join Class Action for Recovery

Legal Call to Action for Pacira BioSciences Investors

The Gross Law Firm has initiated an important notice for shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX) in reaction to significant losses incurred by investors. According to the firm's announcement dated January 23, 2025, those who purchased shares during a designated class period are urged to get in touch with the firm concerning a potential class action lawsuit aimed at recovering their financial losses.

Understanding the Allegations

For context, the allegations against Pacira stem from a critical legal development disclosed on August 9, 2024. The company issued a press release regarding its ongoing litigation with eVenus over patent infringement. The court's ruling determined that Pacira's U.S. Patent No. 11,033,495, which protects Exparel—a product accounting for approximately 80% of the company's revenue—was deemed invalid. This resulted in a catastrophic drop in the stock's value, plummeting from $22.36 per share on August 8 to a low of $11.70 the following day. This drastic decline—over 47%—has raised substantial concerns among investors regarding the stability of the company and the validity of its other patents.

Key Dates for Shareholders

The firm highlights a crucial deadline on March 14, 2025, for those wishing to take a more active role in the lawsuit by applying for lead plaintiff status. While registration as a lead plaintiff isn’t a requirement for recovery, doing so can provide a more engaged role in the legal proceedings. Interested shareholders can register their information through the firm’s dedicated portal without any associated costs.

Potential Consequences for Pacira

The ramifications of the ruling extend beyond immediate stock price drops. Analysts have voiced concerns that the invalidation of the '495 patent could open the doors for increased generic competition in the market, leading to further revenue losses for Pacira and potentially resulting in inflated litigation costs as the company seeks to defend its other patents. This situation may possibly signal ongoing volatility for shareholders moving forward.

The Importance of Legal Action

The Gross Law Firm emphasizes its role as a protector of investor rights, especially for those affected by false statements or omissions made by companies, which can lead to harm and financial setbacks. Engaging in this class action is viewed as an opportunity for affected shareholders to reclaim some of their lost investments.

Next Steps for Interested Investors

To facilitate participation, shareholders are encouraged to visit the specified link for registration. By doing so, they will also gain access to a portfolio monitoring system that will keep them informed on the case's progress and provide updates throughout the litigation process.

In conclusion, shareholders who faced losses due to the latest developments at Pacira BioSciences are strongly encouraged to act promptly and consider joining this class action. The repercussions of the court's decision could have lasting impacts on both the company's operations and the investments held by shareholders.

For further information or inquiries, shareholders can contact The Gross Law Firm at:
15 West 38th Street, 12th Floor
New York, NY 10018
Email: [email protected]
Phone: (646) 453-8903